{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:52:37Z","timestamp":1759938757684,"version":"3.40.5"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"SymbioCellTech"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Globally, individuals with autoimmune Type 1 diabetes mellitus (T1DM) continue to depend for survival on insulin injections. While pancreas and intrahepatic pancreatic islet transplants can produce insulin-independence and ameliorate serious complications, both therapies depend on potentially toxic anti-rejection drugs. Furthermore, the scarcity of pancreas donors and islet transplant failures limit the general availability of such interventions. Recently, fetal and induced Pluripotent Stem Cells have been successfully differentiated to generate insulin producing \u03b2-like cells that generate euglycemia in diabetic mice. However, their clinical use still depends on anti-rejection drugs or immune-isolating encapsulation systems. We reported recently that allogeneic \u201cNeo-Islets\u201d (NI), 3-D organoids of Mesenchymal Stromal and Islet Cells are immune protected and permanently correct autoimmune diabetes in NOD mice by omental engraftment and endocrine cell redifferentiation. This new \u201cendocrine pancreas\u201d delivers islet hormones physiologically into the hepatic portal vein. Furthermore, treatment of insulin-dependent dogs with allogeneic canine NIs (ongoing FDA-approved Pilot Study) consistently improved glycemic control without the need for antirejection drugs. As there remains a critical need for curative therapies of T1DM, we engineered human NIs and tested their ability, after i.p. administration, to reestablish euglycemia in streptozotocin (STZ)-diabetic NOD\/SCID mice. This diabetes model reproduces, in part, the clinical situation in which recipients of allogeneic biotherapies must take potent anti-rejection drugs that similarly create a life-long immune-compromised status. The present study demonstrates that human NI therapy (2x10e5\/kg bw NIs\/mouse) of STZ-diabetic NOD\/SCID mice (n = 6), compared to controls (n = 6) significantly improved glycemic control, and most importantly, that a second dose given to the initial group normalized blood glucose levels long-term. Conclusion: Despite the limitations of the utilized diabetic NOD\/SCID mouse model, the obtained data show that human NIs are curative, an observation that has high translational relevance and significantly supports the planned conduct of clinical trials with human NIs.<\/jats:p>","DOI":"10.1371\/journal.pone.0259043","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T17:45:23Z","timestamp":1635443123000},"page":"e0259043","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Intraperitoneal administration of human \u201cNeo-Islets\u201d, 3-D organoids of mesenchymal stromal and pancreatic islet cells, normalizes blood glucose levels in streptozotocin-diabetic NOD\/SCID mice: Significance for clinical trials"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2349-9874","authenticated-orcid":true,"given":"Christof","family":"Westenfelder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuma","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"pone.0259043.ref001","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2337\/dc12-0063","article-title":"Improvement in outcomes of clinical islet transplantation: 1999\u20132010","volume":"35","author":"FB Barton","year":"2012","journal-title":"Diabetes Care"},{"key":"pone.0259043.ref002","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMra1110560","article-title":"The Past 200 Years in Diabetes","volume":"367","author":"KS Polonsky","year":"2012","journal-title":"N Engl J Med"},{"key":"pone.0259043.ref003","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/s-2000-8127","article-title":"Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506\/Tacrolimus","volume":"108","author":"T Lohmann","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"pone.0259043.ref004","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2337\/db09-0588","article-title":"Redox Modulation Protects Islets From Transplant-Related Injury","volume":"59","author":"MM Sklavos","year":"2010","journal-title":"Diabetes"},{"key":"pone.0259043.ref005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.mpa.0000203961.16630.2f","article-title":"Prospective and Challenges of Islet Transplantation for the Therapy of Autoimmune Diabetes","volume":"32","author":"AN Balamurugan","year":"2006","journal-title":"Pancreas"},{"key":"pone.0259043.ref006","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2337\/db06-0173","article-title":"Sirolimus Is Associated With Reduced Islet Engraftment and Impaired \u03b2-Cell Function","volume":"55","author":"N Zhang","year":"2006","journal-title":"Diabetes"},{"key":"pone.0259043.ref007","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2337\/dc09-0744","article-title":"Safety and Viability of Microencapsulated Human Islets Transplanted Into Diabetic Humans","volume":"32","author":"BE Tuch","year":"2009","journal-title":"Diabetes Care"},{"key":"pone.0259043.ref008","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1007\/s00125-013-2921-1","article-title":"Islet encapsulation: advances and obstacles","volume":"56","author":"GC Weir","year":"2013","journal-title":"Diabetologia"},{"key":"pone.0259043.ref009","doi-asserted-by":"crossref","first-page":"19054","DOI":"10.1073\/pnas.1317561110","article-title":"Transplantation of human islets without immunosuppression","volume":"110","author":"B Ludwig","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"pone.0259043.ref010","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nm.4030","article-title":"Long-term glycemic control using polymer-encapsulated human stem cell\u2013derived beta cells in immune-competent mice","volume":"22","author":"AJ Vegas","year":"2016","journal-title":"Nat Med"},{"key":"pone.0259043.ref011","doi-asserted-by":"crossref","first-page":"e37004","DOI":"10.1371\/journal.pone.0037004","article-title":"A scalable system for production of functional pancreatic progenitors from human embryonic stem cells","volume":"7","author":"TC Schulz","year":"2012","journal-title":"PLoS One"},{"key":"pone.0259043.ref012","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14712598.2020.1748596","article-title":"Cell therapy for type 1 diabetes","volume":"20","author":"C Loretelli","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"pone.0259043.ref013","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/sctm.17-0005","article-title":"Durable Control of Autoimmune Diabetes in Mice Achieved by Intraperitoneal Transplantation of \u201cNeo-Islets,\u201d Three-Dimensional Aggregates of Allogeneic Islet and \u201cMesenchymal Stem Cells\u201d","volume":"6","author":"C Westenfelder","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"pone.0259043.ref014","doi-asserted-by":"crossref","first-page":"e0218688","DOI":"10.1371\/journal.pone.0218688","article-title":"Interim report on the effective intraperitoneal therapy of insulin-dependent diabetes mellitus in pet dogs using \u201cNeo-Islets,\u201d aggregates of adipose stem and pancreatic islet cells (INAD 012\u2013776)","volume":"14","author":"A Gooch","year":"2019","journal-title":"PLoS One"},{"key":"pone.0259043.ref015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cmet.2014.03.010","article-title":"Pancreatic \u03b2 Cell Dedifferentiation in Diabetes and Redifferentiation following Insulin Therapy","volume":"19","author":"Z Wang","year":"2014","journal-title":"Cell Metab"},{"key":"pone.0259043.ref016","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1089\/scd.2010.0009","article-title":"Persistent High Glucose Concentrations Alter the Regenerative Potential of Mesenchymal Stem Cells","volume":"19","author":"C Cramer","year":"2010","journal-title":"Stem Cells Dev"},{"key":"pone.0259043.ref017","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1479-5876-11-115","article-title":"Stromal cell derived factor-1alpha protects stem cell derived insulin-producing cells from glucotoxicity under high glucose conditions in-vitro and ameliorates drug induced diabetes in rats","volume":"11","author":"M Tariq","year":"2013","journal-title":"J Transl Med"},{"key":"pone.0259043.ref018","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cell.2014.09.040","article-title":"Generation of Functional Human Pancreatic \u03b2 Cells In Vitro","volume":"159","author":"FW Pagliuca","year":"2014","journal-title":"Cell"},{"key":"pone.0259043.ref019","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nrneph.2009.229","article-title":"Mesenchymal stem cells: a new therapeutic tool for AKI","volume":"6","author":"FE T\u00f6gel","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"pone.0259043.ref020","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.ajkd.2012.08.034","article-title":"Kidney Protection and Regeneration Following Acute Injury: Progress Through Stem Cell Therapy","volume":"60","author":"FE T\u00f6gel","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"pone.0259043.ref021","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"KJ Livak","year":"2001","journal-title":"Methods"},{"key":"pone.0259043.ref022","first-page":"6","article-title":"Determining significant fold differences in gene expression analysis","author":"AJ Butte","year":"2001","journal-title":"Pac Symp Biocomput"},{"key":"pone.0259043.ref023","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-8587(18)30078-0","article-title":"Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial","volume":"6","author":"S Lablanche","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pone.0259043.ref024","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/B978-1-4377-0324-5.00032-8","volume-title":"Williams Textbook of Endocrinology","author":"GS Eisenbarth","year":"2011","edition":"12"},{"key":"pone.0259043.ref025","doi-asserted-by":"crossref","first-page":"204-LB","DOI":"10.2337\/db20-204-LB","article-title":"204-LB: The In Vitro Characteristics of Human Islet Cells from Diverse Donors, Coaggregated with Human Mesenchymal Stromal Cells to form \u201cNeo-islets\u201d, Are Consistently Identical: Relevance to Clinical Trials in Diabetic Subjects","volume":"69","author":"A Gooch","year":"2020","journal-title":"Diabetes"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0259043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T17:45:44Z","timestamp":1635443144000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0259043"}},"subtitle":[],"editor":[{"given":"Paolo","family":"Fiorina","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0259043","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,10,28]]}}}